Case series of complex therapy of hemoblastosis in the context of COVID-19

Abstract

Introduction: The COVID-19 pandemic is a problem of a global scale, and it has an importance in modern oncology and hematology. Patients with cancer are at high risk of getting infected with COVID-19. Diagnosis of coronavirus infection in such patients entails the cancellation of chemotherapy for an indefinite period. A break between courses of treatment, as well as a complete cancellation of therapy, can increase the mortality of patients from oncohematological diseases. Material and methods: From June to October 2020, based on the Oncohematological Department of the National Research Oncology Center LLP, 19 patients were treated, of which: men - 11, women - 8. Average age - 43 years (+ -16). Of these, patients with multiple myeloma - 32%; acute myeloid leukemia - 26%; acute promyelocytic leukemia - 11%; acute lymphoblastic leukemia - 26%; chronic lymphocytic leukemia - 5%. Treatment was carried out following the protocols for the diagnosis and treatment of hemoblastosis and concomitant COVID-19 infection. Results: This article presents clinical cases of complex therapy of patients with hemoblastosis and concomitant COVID-19 infection who were treated in a hospital.

Keywords

• COVID-19
• hemoblastosis
• multiple myeloma
• chemotherapy
• autologous stem-cell transplantation
• acute myeloid leukemia